Although development leads unidirectionally toward more restricted cell fates, recent work in cellular reprogramming has proven that one cellular identity can strikingly convert into another, promising countless applications in biomedical research and paving the way for modeling diseases with patient-derived stem cells. To date, there has been little discussion of which disease models are likely to be most informative. Here, we review evidence demonstrating that, because environmental influences and epigenetic signatures are largely erased during reprogramming, patientspecific models of diseases with strong genetic bases and high penetrance are likely to prove most informative in the near term. We also discuss the implications of the new reprogramming paradigm in biomedicine and outline how reprogramming of cell identities is enhancing our understanding of cell differentiation and prospects for cellular therapies and in vivo regeneration.
Although development leads unidirectionally toward more restricted cell fates, recent work in cellular reprogramming has proven that one cellular identity can strikingly convert into another, promising countless applications in biomedical research and paving the way for modeling diseases with patient-derived stem cells. To date, there has been little discussion of which disease models are likely to be most informative. Here, we review evidence demonstrating that, because environmental influences and epigenetic signatures are largely erased during reprogramming, patientspecific models of diseases with strong genetic bases and high penetrance are likely to prove most informative in the near term. We also discuss the implications of the new reprogramming paradigm in biomedicine and outline how reprogramming of cell identities is enhancing our understanding of cell differentiation and prospects for cellular therapies and in vivo regeneration.
As a zygote cleaves and then develops into a complex organism, cells transition inexorably from one identity to another. Gene expression from a single genome naturally evolves and adapts via a carefully choreographed and directed set of inductive and selective events until lineages become segregated and tissue fates are fixed. This ability of a multicellular organism to create diverse cell types from a single stable genome provides versatility of function, permitting an organism to adapt and thrive in more varied environments than their single-cell predecessors. Although a few complex organisms, such as salamanders, regenerate large portions of their bodies by dedifferentiating their tissues, most multicellular organisms demonstrate very little reversibility of cellular identity after completing embryogenesis. Adult mammals are unable to regenerate anatomically correct organ systems after significant damage or loss, demonstrating that cellular identities in the unaffected tissues are largely stable. Even in the few mammalian organs with high rates of cell turnover, such as the skin, blood system, and gut, the range of possible cell fates is rigidly restricted to those cellular identities comprising the specific tissue.
Evolution has invested heavily in maintaining and restricting cellular identities in mammals. Once a mammalian cell has progressed through its natural developmental and regenerative transitions, its final, specialized state is sustained by a loss of self-renewal and inevitable senescence. Mutations in the genetic mechanisms of cellular identity, stability, and senescence predispose cells to the development of malignancy. For example, when granulocyte macrophage precursors acquire self-renewal, these otherwise normal progenitors are transformed into leukemic stem cells (Krivtsov et al., 2006) . Pathologic conditions that encourage fluidity of cellular identity can similarly predispose individuals to cancer. Patients with gastresophageal reflux are a classic example of this phenomenon, in which exposure to stomach acid causes affected regions of the esophagus to transform into stomach-like tissue. This tissue metaplasia, while protecting the integrity of the esophagus, also predisposes patients to adenocarcinoma (Lagergren et al., 1999) . The in vivo mechanisms by which a differentiated cell transitions to another cell type (metaplasia) or to a more undifferentiated phenotype (dysplasia) are under investigation. Current research suggests that these in vivo alterations of cellular identities are brought about by changes in the epigenome and gene expression of the affected cells, which in turn provide fertile ground for the appearance of mutations that promote malignant transformation (Kang et al., 2003; Nardone et al., 2007; Herfs et al., 2009) .
Manipulating Cellular Identity In Vitro
The orderly progression of cell differentiation during development has been well described by in vivo studies, but some questions can be addressed more directly in the highly controlled environment of in vitro tissue culture. Human embryonic stem (ES) cells, derived from the inner cell masses of human blastocysts, were first successfully derived less than 15 years ago by the Thomson group from the University of Wisconsin (Thomson et al., 1998) . Pluripotent cells are unique in that they can be grown indefinitely while retaining the ability to differentiate into all three embryonic tissue lineages. Human ES cell derivation has inspired biomedical scientists to use stem cells to address questions of human developmental biology, to study disease processes in vitro, and even to attempt to replace ailing tissues in human patients. All of these hopes have been pinned on the ability of scientists to engineer specific cellular identities. This is an ambitious goal. Murine ES cells have been in widespread use for three decades, and yet attempts to generate functional mouse blood cells, pancreatic cells, and highly specialized neurons have so far proven only partly successful. Nonetheless, biologists remain confident that ES cells can be differentiated to specific cell types if culture conditions can be identified that precisely mimic the organizational and signaling events of the developing embryo. This approach necessitates an in-depth understanding of the cellular identity changes that take place in normal development and requires direct translation of basic developmental biology into painstakingly developed protocols for directed differentiation.
During in vitro differentiation, stem cells are induced to form aggregates with predictable structures (i.e., embryoid bodies) that echo embryonic organization, and growth factors have been identified that coax pluripotent cells toward one lineage or another. These approaches attempt to recapitulate the epigenetic changes that occur during embryogenesis, with the aim of creating tissue types analogous to those generated during embryonic development. In the years since the first human ES cell derivation, scientists have crafted differentiation protocols to generate many cell types, including motor neurons, retinal pigment epithelium, and hematopoietic precursors from human ES cells (Wichterle et al., 2002; Klimanskaya et al., 2004; Ng et al., 2005) . These protocols exemplify the reigning paradigm that in vitro manipulations of cellular identity should follow the course of the natural, unidirectional changes that occur during development.
This paradigm was overthrown in 2006, when Takahashi and Yamanaka published the distinctly unnatural conversion of murine fibroblasts into induced pluripotent stem (iPS) cells (Takahashi and Yamanaka, 2006) . Their approach was blatantly not based on mimicking developmental events, and the cellular fate change that they engineered went backward-the implausible reversion of a differentiated, specialized somatic cell to a pluripotent embryonic progenitor.
Although conversion of differentiated cells to an embryonic state had previously been accomplished by somatic cell nuclear transfer, that process was and remains to this day inefficient, cumbersome, and poorly understood (Rideout et al., 2001 ). The Yamanaka reprogramming approach, on the other hand, used a few defined factors to convert a cell to a radically different identity. This landmark study compelled a bold paradigm shift and introduced the engineering of cell identity as a powerful new strategy for biomedical research and regenerative medicine.
The pluripotency of murine iPS cells has been established in many ways, including gene expression and epigenome profiling, chimera formation, and tetraploid embryo complementation (Okita et al., 2007; Zhao et al., 2009) . Soon after the publication of reprogramming in murine cells, multiple labs confirmed that ectopic expression of defined factors could also generate iPS cells from human tissues (Yu et al., 2007; Takahashi et al., 2007; Park et al., 2008b) . Both gene expression and epigenetic studies revealed that iPS cells are strikingly more similar to ES cells than they are to their starting cell type (Hawkins et al., 2010; Doi et al., 2009; Kim et al., 2010; Polo et al., 2010) , showing that transduction of four transcription factors (i.e., Oct4, Sox2, Klf4, and c-Myc) indeed alters mammalian cellular identities in the direction opposite to that of development. Although multiple groups had induced modest cell fate changes between mesodermal or hematopoietic lineages by manipulating transcription factors (Davis et al., 1987; McNagny and Graf, 2002; Cobaleda et al., 2007) , engineering cell fate changes as dramatic as reversion of differentiated cells to pluripotency was not envisioned as plausible before Yamanaka's work.
The original publication of iPS cell reprogramming has inspired researchers to attempt manipulations of cellular identity in new and unexpected directions. Ectopic transcription factor expression is now being investigated as a tool to perform direct conversion, or ''transdifferentiation,'' of one differentiated cell type to another, including neurons and cardiomyocytes from fibroblasts and b cells from exocrine cells (Zhou et al., 2008; Vierbuchen et al., 2010; Ieda et al., 2010; Efe et al., 2011) . Protocols continue to be published for the generation of differentiated cell types from pluripotent stem cells, for more effective generation of stem cells from somatic cells, and for the conversion of one differentiated cell type to another.
This diversity of goals represents a radical change in thinking about the categories of identity changes that can be effected in vitro (Figure 1 ): adult mammalian cellular identity can be manipulated not only in the direction of stem cell differentiation (a correlate of normal development), but also dedifferentiation (a correlate of dysplasia) and transdifferentiation (a correlate of metaplasia). The recent appreciation for the plasticity of cellular identity has made this area one of the most exciting topics in modern stem cell biology. Takahashi and Yamanaka's seminal publication has compelled a new and creative open-mindedness Cellular identity is the sum of a cell's epigenetic landscape. It can become altered through numerous in vivo processes, including development, metaplasia, and dysplasia. It can also be manipulated by experimenters in protocols such as directed differentiation, transdifferentiation, and reprogramming. about cellular identity and has paved the way for the development of iPS cell-based disease models, drug screens, and cellular therapies. The prospects for cellular therapies are still on the horizon, but use of reprogramming technology for disease modeling and drug testing has already begun. This Perspective provides a discussion on which disease categories are likely to benefit in the near future from reprogramming-based models and how these models can be used to study gene-environment interactions.
Reprogramming-Based Disease Models Provide a New Platform for Disease Research
Research into human disease can be performed on platforms as diverse as epidemiology, human genetics, animal modeling, and in vitro cell culture. Each of these approaches provides different kinds of information about the disease under investigation, and each has its own limitations. It is not often that a new platform for studying disease arises, but in the last few years, the advent of patient-specific pluripotent stem cells has inspired researchers to contemplate modeling diseases in a powerful new way.
By differentiating patient-specific iPS lines into the cell type responsible for a specific disorder, scientists hope to gain many new research tools. For disorders in which etiology is unclear, such as type I diabetes, it is theorized that patientspecific iPS cell models may confirm current theories or inspire new hypotheses about the origins and progression of the disease (Maehr et al., 2009) . For diseases in which humanspecific cardiac or renal toxicity is a limiting factor in treatment, stem cell-derived models of heart or renal tissues may be used to experimentally measure and reduce drug associated toxicity. Finally, for any disorder whose iPS cell-derived target cells show a measurable disease-specific phenotype, reprogramming-based models can be used as screening tools for development of new drugs that reverse the cellular pathology in vitro and might therefore carry a greater probability of reversing disease pathology when given to patients.
Because of the inherent pluripotency of the starting cells, their potential applications for cell-autonomous disorders touch virtually every organ system. Researchers studying disorders of hematological, neurological, cardiovascular, metabolic, endocrine, and muscular cell types have already begun the process of creating disease models by reprogramming disease-specific primary cell samples from patients with cystic fibrosis, Huntington's disease, Parkinson's disease, sickle cell anemia, dyskeratosis congenita, familial amyotrophic lateral sclerosis, and a growing compendium of other conditions recently reviewed by Grskovic et al. (2011) (Park et al., 2008b; Dimos et al., 2008; Mali et al., 2008; Somers et al., 2010; Ghodsizadeh et al., 2010; Agarwal et al., 2010) . These inexhaustible sources of patient-specific cells are then differentiated toward the lineage affected by the disorder, be it neural, hematopoietic, cardiac, or hepatic. Once the cell type that is responsible for the disease has been generated, researchers attempt to identify a diseaseassociated phenotype that manifests characteristics relevant to the disorder. Such cells represent a new research platform for studying both mechanisms and genotype-phenotype interactions of the disease.
For example, congenital long-QT syndrome has been difficult to study in vitro because of the inaccessibility of human cardiomyocytes carrying the causal genetic mutations (Behr et al., 2008) . In a recent study by Moretti et al., iPS cells were derived from individuals with monogenic congenital long-QT syndrome type I, differentiated to cardiac lineages, and assayed for characteristic electrophysiological traits (Moretti et al., 2010) . The patient-derived cardiomyocytes showed longer-lasting action potentials than the healthy controls, as well as an altered protein localization pattern. These findings allowed the authors to identify a dominant-negative mechanism of disease. A paper released shortly afterward described similar studies on another variant of congenital long-QT syndrome, caused by a mutation in a different gene (Itzhaki et al., 2011) . This study identified additional disease-associated electrophysiological phenotypes in the patients' cells, and the authors were able to conduct a limited drug screen to investigate the potency of chemical compounds to ameliorate the disease traits. The existence of these two models will allow for direct comparison of cellular phenotypes between different genotypes of the same disease and will hopefully lead to improved, personalized therapeutic options for patients ( Figure 2 ).
Because of these many and varied benefits, reprogrammingbased disease models are being rapidly adopted by translational scientists. Dozens have already been published and are the subject of recent review articles (Grskovic et al., 2011; Tiscornia et al., 2011; Unternaehrer and Daley, 2011) . However, the field of iPS cell-based disease modeling is still in its infancy, and many challenges remain. Most disease systems still face significant hurdles that need to be overcome before iPS technology can deliver on its promise. The following are specific challenges that each disease field must address. Directed Differentiation and Cell Culture Protocols For many years, work has been underway to convert pluripotent cells into target cell types. Some highly specialized cell types like motor neurons and cardiomyocytes have been created with great fidelity using protocols that mimic pathways defined through studies of embryo development. In contrast, only close facsimiles of other much sought-after cell types, like b cells, have been created using independent protocols in different laboratories, with phenotypes that differ from actual human target cells (Kroon et al., 2008; Zhang et al., 2009) . Some cell types, such as definitive hematopoietic stem cells (HSCs), have never been successfully derived from pluripotent stem cells purely in vitro. In cases like HSCs, the difficulty rests in large part on the lack of suitable culture conditions to maintain and expand these evanescent cells. Where cell culture conditions remain poorly defined, directed differentiation protocols represent a critical rate-limiting step in iPS cell research. Definition of ''Target'' Cell Cellular identity is a complex phenotype with many components. For research to proceed on a given iPS cell-derived cell type, the field must first agree that the in vitro product is comparable to its in vivo correlate. This measure of similarity must occur on multiple levels and include analysis of gene expression, chromatin state, and functional assays. Transcriptional activity and methylomes can be evaluated by similar methodologies in all cell types, but appropriate markers of cell identity as well as choice and validation of cell type-specific functional assays must be specifically identified for all target cell types. Identification of Appropriate Disease-Specific Cellular Phenotypes In some cases, target cell types derived from disease-specific iPS cells show clear and predictable phenotypes, such as the electrophysiological abnormalities in the cardiomyocytes described above. For other diseases, the appropriate assay for disease phenotype is unclear or may not show a significant difference between disease and nondisease lines. For example, recent papers have derived iPS lines from patients with idiopathic Parkinson's disease (PD) and normal controls (Soldner et al., 2009; Hargus et al., 2010) . The researchers planned to investigate whether PD-iPS cell lines would form dopaminergic neurons at lower frequencies than WT-iPS cells during directed differentiation, as well as how dopaminergic neuron grafts would function in transplantation assays into various animal models of PD. In practice, none of these endpoints showed any difference between the disease and the control-derived iPS cells. The researchers eventually identified only a single outcome measure in the rodent model that showed a significant difference between the two cell types out of three behavioral tests that were administered after PD was induced.
This case underscores the difficulty that befalls the investigator when deciding whether a true phenotypic difference indeed reflects the underlying disease pathophysiology. In another recent paper investigating progeria, the search for a stress-related phenotype in iPS-derived cells led to creative assays such as submersing cells in oil for 5 hr or exposing them to electrical stimulation for 3 days (Zhang et al., 2011a) . As the search for new disease models expands, cases like this should serve as an instructive reminder that investigators are responsible for demonstrating that their ''disease-associated phenotypes'' are biologically relevant to the disease at hand.
Identification of Diseases Amenable to iPS Cell-Based Modeling
To date, there has been little discussion about which disorders are likely to be best informed by iPS cell models. The idiopathic PD example is a cautionary tale that disease modeling with iPS cells will be more informative for some types of disease than for others. Reprogramming may still be too new of a technical advance to reliably predict which diseases can be effectively modeled and which will not. However, in the long term, it will behoove the field to establish a methodology for analyzing successful and unsuccessful modeling attempts to identify the factors that predict success. Considerations are discussed below for determining whether a particular disease research field is likely to be well served by reprogramming-based models. Identification of Disorders Best Suited to ES Cell-Based Disease Modeling Disease-specific ES lines from preimplantation genetic diagnosis are likely to be better suited for research on certain questions than iPS cell lines. One example of this is fragile X syndrome (FX), in which the FMR1 gene is inappropriately silenced during development. Because of a failure to reactivate the mutant locus during reprogramming (Urbach et al., 2010) , FX-iPS cells do not express the FMR1 gene. Thus, though FXiPS cells may give rise to FMR-deficient neurons (Sheridan et al., 2011) , they do not allow studies of the mechanisms by which pathological gene silencing occurs during development.
Reprogramming Imperfectly Resets the Epigenome to an ES Cell-Like State
Several studies have compared the epigenetic status of iPS cells to that of ES cells and the starting somatic cell type. The global methylation profiles of iPS cells are much closer to ES cells than they are to their tissue of origin (Doi et al., 2009; Lister et al., 2011) , reflecting the phenotypic and functional similarities shared by the pluripotent cells and confirming that the reprogramming process resets the vast majority of the iPS cell epigenome to an ES-like state. However, the epigenomes of the two pluripotent cell types are not identical.
Specific classes of epigenetic marks have been reported to escape reprogramming's broad epigenetic erasure. While attempting to differentiate iPS cell lines derived from different tissues into various lineages, our laboratory noted that the reprogrammed cells tended to differentiate preferentially into the lineage from which they were originally derived, and in some cases, they retain residual methylation reflective of the donor cell. These data argue that iPS cells have an epigenetic memory in which a small number of epigenetic marks fail to be reset during reprogramming, apparently at random (Kim et al., 2010 . Another recent paper identified randomly located methylation differences between iPS and ES cells. The authors noted that the methylation profiles of the iPS lines became more and more like those of the ES cells upon continued passage (Nishino et al., 2011) . Other studies have found that certain chromosomal regions near telomeres and centromeres may be particularly resistant to epigenetic erasure during reprogramming and that DNA methylation differences in these regions may be maintained even during differentiation (Lister et al., 2011) .
Studies on Prader-Willi and Angelman syndromes have also described the fate of imprinted genes during reprogramming (Chamberlain et al., 2010; Yang et al., 2010) . To the surprise of the authors, these disease-associated gene imprints were unaltered during iPS cell generation. These results suggest that, although the majority of developmentally accrued methylation marks are reset during reprogramming, the process does not revert cellular identity all the way back to a pre-imprinting epigenetic state.
Sources of Epigenetic Variation In Vivo: Environment and Stochasticity
Environmental exposures have long been known to introduce changes into the epigenome. Although most environmental events are only transient phenomena, they often have a lasting effect on cellular behavior by causing changes to the epigenome. Cells modify their transcriptional activity in response to chemical exposures, nutrition, or physical stress, and such changes can be an enduring legacy of a significant environmental event (Bell and Spector, 2011; Waterland and Jirtle, 2004; McGowan et al., 2009; Anway et al., 2006) .
Stochastic processes also introduce variability to epigenetic organization. The fidelity of inheriting site-specific maintenance of methylation in humans has been estimated at 90%-98% (Ushijima et al., 2003; Genereux et al., 2005) . However, even this modest error rate makes it clear that variation is introduced into the methylome with every cell division at a much higher rate than DNA sequence mutations would ever accumulate. Unlike epigenetic modifications that may occur predictably in response to environmental events, this type of change in DNA methylation occurs randomly.
Between environmentally induced and stochastic epigenetic changes, over time, an individual's epigenome is slowly altered to reflect the events of his or her individual experiences (Wong et al., 2010) . Some individuals may also have a genetic predisposition to large or small epigenetic oscillations (Bjornsson et al., 2008; . Given that some or many of these changes will effect gene expression, an individual's epigenetic signature determines how their cells will react in certain circumstances, and so can predispose to disease or health.
Genetic, Environmental, and Epigenetic Contributions to Complex Diseases
Despite possessing identical genomes, it is common for one monozygotic twin to suffer from a complex disease while the other is unaffected. Monozygotic twins are often discordant for multifactorial disorders that strike later in life, such as schizophrenia, type II diabetes, and Parkinson's disease. Traditionally, phenotypic variability has been viewed as the sum of genetic variability and environmental variability (Visscher et al., 2008) , such that all differences between monozygotic twins are due to the shared genotype's reactions to different environments. However, this view commingles the effects of immediate environmental exposures and lasting epigenetic changes, and it also ignores epigenetic alterations caused either by stochastic processes or by genetic predisposition to variability. Failure to distinguish between causal environmental exposures and causal epigenetic changes may impair our ability to identify and analyze appropriate phenotypes of in vitro models of disease. Thus, when considering disease etiology for modeling, it may be more informative to view cellular disease phenotypes as having three classes of contributing factors, each of which is transmitted differently.
Genetic Predisposition. Variations in DNA sequence can increase or decrease the likelihood of a cellular phenotype.
DNA sequences are transmitted fully and accurately during cell division.
Environmental Exposures (Nonepigenetic). Immediate environmental conditions impact cell health and behavior, such as nutritional deficiency, hyperglycemia, or chemical exposure. These conditions are external and not transmittable to daughter cells.
Epigenetic Effects. These stable and highly transmissible changes in gene expression are caused by (1) environmental events, (2) stochastic epigenetic changes, and (3) genetic predisposition to variability.
With this in mind, human illness can be viewed as the sum of the genetic, environmental, and epigenetic factors (Petronis, 2006 ). Attempts to model diseases by iPS cell-derived approaches should take all of these into account. A few rare disorders are caused by a single one of these effects, but many common diseases have the full triad of causes. Here, we first examine examples of these rare, single-factor disorders, and then we discuss the more common phenomenon of multifactorial disease.
Genetic Diseases
Monogenic disorders are those diseases in which a single gene is responsible for the presence, absence, or severity of a particular phenotype. The gene variants that are responsible for these types of disorders include the CAG repeats of Huntington's disease, the mutant clotting factors in hemophilia, and the altered ion channels in congenital long QT syndrome. There also may be multigenic conditions in which the combination of specific gene variants causes disease regardless of environmental or epigenetic effects or in which somatic mutation causes the disease. For disorders in which the DNA sequence is responsible for the disease, iPS cells generated from cells with this sequence will bear the causal genotype. Whether or not the responsible locus or loci have been identified, when patientspecific iPS cells are differentiated into relevant cell types, the same genetic defect that caused the patient's disorder will be present in the differentiated cells.
Environmental Diseases
Environmental exposure disorders are those in which an environmental condition directly causes the ailment. In the case of a skin burn caused by exposure to boiling water, 100% of the observed burn phenotype is attributable to the environmental exposure. There is no epigenetic or genetic cause, and the heritability is zero. Comparing iPS cells generated from a patient who has sustained a burn to iPS cells from someone who has not been burned is unlikely to yield information relevant to burn pathophysiology. Epigenetic Diseases Epigenetic disorders are those in which the phenotype is caused by an epigenetic state of the genome. This may be entirely due to the aberrant expression pattern of a single gene, as in rare syndromes like fragile X or Prader-Willi, or the much more common global misregulation in which innumerable environmentally induced and stochastic epigenetic events affect overall disease predisposition . Although the single genes responsible for fragile X or Prader-Willi are individually regulated during development and thus appear to be resistant to epigenetic change during reprogramming, the countless small epigenetic modifications that predispose an individual to complex disease are more likely to be erased during the reprogramming process. As noted above, epigenetic variation can arise in response to environmental exposures stochastically and even in response to specific genotypes. Regardless of the source of the epigenetic change, in a few rare conditions, 100% of the observed phenotype is due to epigenetic variation. Phenotypes caused by epigenetic changes include phenomena such as neural tube malformations after global DNA hypomethylation. It has not yet been investigated whether the flawed epigenomes underlying disorders like this one will remain after iPS cell generation. However, given the widespread reprogramming of the epigenetic status of the cells, such perpetuation seems unlikely.
If a disease does not fall cleanly into one of the three categories above, then the phenotypic variation is a sum of the triad of genetic, epigenetic, and environmental variations. An example of such a condition is sunburn after exposure to the sun's ultraviolet radiation. In this case, the genetic makeup of the individual, as it relates to skin pigmentation, contributes to resistance or predisposition to burning upon exposure to sunlight. In addition, recent ultraviolet exposure that induces genes that produce the photoprotectant melanin may also contribute to burn protection. And finally, intensity and duration of exposure to the damaging radiation will affect the severity of the resulting burn. A reprogramming-based model of sunburn would need to take all three of these factors into account to reproduce a physiologically accurate in vitro model of sunburn.
An interesting subset of complex disorders has both familial and sporadic inheritance patterns but drastically different heritability values. For example, the familial PD variant caused by the a-synuclein A53T mutation has a heritability of nearly 100%, whereas the diagnosis of idiopathic PD is estimated to show lower heritability of only 30%-40% (Golbe et al., 1990; Hamza and Payami, 2010; Do et al., 2011) . Although familial versions of common complex diseases often have distinctive features such as age of onset and severity of symptoms, the underlying cellular pathology often appears consistent between familial and idiopathic versions of disease (e.g., the loss of dopaminergic neurons from the substantia nigra in PD).
Value of Stem Cell-Based Disease Modeling
Patient-Specific Disease Modeling Will Be Most Useful for Diseases with Large Genetic Components During reprogramming of somatic cells to pluripotency, epigenetic histories are erased, and standard tissue culture conditions normalize all environmental differences. Of the genetic, environmental, and epigenetic variations that lead to complex disease, the only source of variation likely to be faithfully maintained in iPS cell lines is the genetic variation (Figure 3) . Table 1 lists publications to date in which iPS cells were derived from patients and subsequently differentiated into the target cells affected by the relevant disorder. Some of these papers observed significant differences between the patientspecific lines and control, whereas others did not. Only one paper has identified a cellular disease phenotype associated with a multifactorial disorder, which was schizophrenia. Schizophrenia is one of the most highly heritable complex disorders, with heritability estimates upwards of 80% (Cardno et al., 1999) . All other publications that have shown disease-associated cellular phenotypes have been investigating genetic disorders (Table 1) .
We predict that the value of patient-specific iPS cell-based disease modeling will be directly proportional to the disease heritability. What then are the prospects for modeling multifactorial diseases with genetic, environmental, and epigenetic components? The field is placing a bet that cells derived from patients who carry a highly penetrant genetic disease predisposition will provide insight into pathologic mechanisms of both the monogenic and multifactorial versions of the disorder.
Is this hope sound? It will be for sporadic forms of disease that have as their molecular underpinnings spontaneously arising mutations in genes that function in the same tissues as the familial forms. These are typically somatic mutations. Consequently, they are expected to show similar cellular pathologies in vitro-if the iPS cells happen to capture the somatically acquired disease-causing mutation. In other cases, a patient with sporadic disease may have a genotype that only predisposes to the disease, perhaps in the setting of specific environmental insults, and thus shows incomplete penetrance. In these cases of complex diseases that show significant heritability but no Mendelian inheritance pattern, the genetic disease predisposition will be present in the stem cell and the resulting model. Finally, it is also possible that, in some cases, the combined environmental and epigenetic influences on the target tissue in an affected patient produce a cellular pathology that mimics that of the genetic version of the disease but that carries no overt or detectable genetic contributor. In this case, reprogramming will erase all vestiges of the environmental insults that caused Healthy control cells can be cultured, reprogrammed to iPS cells, and then differentiated into a target cell type as a control for disease phenotype assays. Cells from patients with monogenic or highly penetrant genetic disease predisposition can be cultured, reprogrammed, and differentiated to the cell type responsible for the disorder. Because the genetic predisposition to disease is present in the final cell, this cell is likely to show disease-specific phenotypes when compared to the healthy control. For diseases caused by environmental and/or epigenetic events, some cell types may not have experienced the causative events. Cells without environmental or epigenetic predisposition to disease can be cultured, reprogrammed, and differentiated, but because they never carried a predisposition to disease, the resulting cells are unlikely to demonstrate a disease-specific phenotype. Cells affected by a disease-causing environmental or epigenetic event can be cultured, in which environmental conditions are standardized, and reprogrammed, in which the epigenome is reset. After these factors are normalized, these cells no longer carry a predisposition to disease. Thus, the iPS lines and differentiated cells resulting from this approach are unlikely to demonstrate disease-specific phenotypes. Cells from any source can be exposed to disease-inducing environmental conditions to create a model of an environmentally induced disorder. This could be during reprogramming (as shown), during differentiation, or during extended culture. Cells from any source can be epigenetically manipulated to mimic epigenetic alterations contributing to disease. Pink, healthy; green, predisposed to disease. Genetic a1-antitrypsin deficiency (Rashid et al., 2010) Genetic Adrenoleukodystrophy, X-linked (Jang et al., 2011) Genetic Alzheimer's disease, familial (Yagi et al., 2011) Genetic Amyotrophic lateral sclerosis, familial (Mitne-Neto et al., 2011) Genetic Atypical Werner syndrome (Cy Ho et al., 2011) Genetic Chronic granulomatous disease, X-linked (Zou et al., 2011b) Genetic Down syndrome (Baek et al., 2009) Genetic Duchenne muscular dystrophy (Kazuki et al., 2010) Genetic Dyskeratosis congenita (Agarwal et al., 2010) Genetic Epidermolysis bullosa (Tolar et al., 2011b) Genetic Familial dysautonomia (Lee et al., 2009) Genetic Fragile X syndrome (Urbach et al., 2010) Genetic Gaucher's disease (Mazzulli et al., 2011) Genetic Glycogen storage disease type 1A (Rashid et al., 2010) Genetic Huntington's disease Genetic Hurler syndrome (Tolar et al., 2011a) Genetic Hutchinson-Gilford progeria (Liu et al., 2011) Genetic Hypercholesterolemia, familial (Rashid et al., 2010) Genetic Inherited dilated cardiomyopathy (Cy Ho et al., 2011) Genetic LEOPARD syndrome (Carvajal-Vergara et al., 2010) Genetic Long QT syndrome (Moretti et al., 2010; Itzhaki et al., 2011; Lahti et al., 2011) Genetic MPS type IIIB (Lemonnier et al., 2011) Genetic Myeloproliferative disorder (Ye et al., 2009 ) Genetic Parkinson's disease, familial (Seibler et al., 2011; Nguyen et al., 2011; Devine et al., 2011) Genetic Retinitis pigmentosa (Jin et al., 2011) Genetic Rett Syndrome (Marchetto et al., 2010) Genetic Sickle cell disease (Zou et al., 2011a) Genetic Spinal muscular atrophy (Ebert et al., 2009) Genetic Timothy syndrome (Ebert et al., 2009) 
Genetic
Wilson's disease (Zhang et al., 2011b) Multifactorial Schizophrenia (Brennand et al., 2011) No Cellular Disease Phenotype Determined
Type Disorder Publication
Genetic ADA-severe combined immunodeficiency (Park et al., 2008a) Genetic Becker muscular dystrophy (Park et al., 2008a) Genetic Crigler-Najjar syndrome (Ghodsizadeh et al., 2010) Genetic Cystic fibrosis (Somers et al., 2010) Genetic Gyrate atrophy (Howden et al., 2011) Genetic Osteogenesis imperfecta (Khan et al., 2010) Genetic Progressive cholestasis, familial (Ghodsizadeh et al., 2010) Genetic Shwachman-Bodian-Diamond syndrome (Park et al., 2008a) Genetic Tyrosinemia type 1 (Ghodsizadeh et al., 2010) Multifactorial Diabetes type 1 (Maehr et al., 2009) 
Multifactorial
Parkinson's disease, sporadic (Soldner et al., 2009; Hargus et al., 2010; Swistowski et al., 2010) Multifactorial Scleroderma (Somers et al., 2010) Most lines to date that have been differentiated into disease-relevant cell types have been from patients with genetic disease. Identifying a diseasespecific phenotype in differentiated cells from patients with multifactorial disease has been less successful than from patients with genetic disease.
the disease, and comparisons of highly heritable familial forms of disease to sporadic cases will prove unrevealing. It is likely that future research will validate each of the above scenarios. Stem Cell-Based Models for Diseases with Significant Environmental or Epigenetic Components Require Experimental Induction of the Disease Despite the erasure of environmental and epigenetic causes of disease by reprogramming, pluripotent stem cell-based models may still prove useful for nongenetic diseases. When the environmental or epigenetic factors responsible for causing disease are well understood, it may be possible to induce them experimentally in culture, even if interactions among distinct cell types are required. For example, by differentiating iPS cells into keratinocytes and melanocytes, which communicate in response to exposure to ultraviolet light (Lin and Fisher, 2007) and could be organized into a facsimile of an epidermis in vitro, the phenomenon of sunburn could be investigated by this experimental platform, as the genetic, epigenetic, and environmental causes are relatively well understood. This leads to a well-controlled triad experimental model, in which as long as two of the three variables are held constant, the third can be manipulated to test hypotheses: (1) iPS cell-derived epidermis could be generated from individuals with inherited sunburn predisposition to learn about the genetic factors affecting the process; (2) various intensities and durations of ultraviolet light could be applied to the epidermis in culture to investigate cellular responses to different severities of environmental exposure; (3) epidermis in culture could be subjected to repeated ultraviolet exposures to induce gene expression leading to melanin formation, allowing for study of the mechanisms by which the environmental exposure leads to the change in gene expression. This triad model (Figure 4 ) would provide a much-needed tool to investigate directly the effects of epigenetic manipulations on cellular disease states. It would also be useful for teasing apart genotype by environment or genotype by epigenetic disease effects because the behavior of cells with various genetic backgrounds could be directly compared. Using this technique to approach diseases of poorly understood etiologies requires a leap of faith that researchers will be able to induce, identify, and exploit a credible cellular pathology. Given that many disorders are late onset, researchers might first discern how to accelerate disease latency from many decades in actual patients to no more than weeks to months in vitro. Moreover, they may be required to re-create the environmental and epigenetic changes induce the cellular phenotype responsible for the disease. A triad model for poorly understood disorders is an admirable goal that will require much work before it bears fruit. Future Benefits In addition to the disease models and drug screens currently being developed, the wholesale conversion of one cell type to another has compelled scientists to entertain new phenomena in cellular and developmental biology, and it has inspired clinicians to conceive new therapeutic opportunities. Myriad diseases are caused by the lack of a crucial cell or an indispensable protein; the ability to cure disease by replacing the missing component is the promise of stem cell engineering and regenerative medicine.
Two broad approaches could be taken to restore a missing cell type: (1) creation of iPS cells followed by directed differentiation into the missing cell type, which would then be incorporated into the patient in an anatomically appropriate fashion, or (2) direct conversion of an extant healthy cell type into the missing or damaged cell type, thus effecting cell regeneration in situ.
The first of these possibilities has many elements in common with the approaches currently being taken to create disease models, requiring GMP reprogramming procedures and precise directed differentiation protocols that eliminate the possibility of stem cell-derived tumors. Diseases of different systems each need an approach for attaining lasting integration of the new cells. This will vary by organ and may be straightforward for some disorders, such as those requiring hematopoietic stem cells, but much more difficult for others, such as neurodegenerative conditions requiring specific neuronal connections to be made.
The second approach to cell therapy would be to manipulate cellular identity in situ to generate the missing cell type in an appropriate anatomical location. A groundbreaking study from the Melton group investigated in vivo conversion of cell types inside the pancreas (Zhou et al., 2008) . They found that infection of pancreatic exocrine cells with viruses expressing developmental pancreatic genes resulted in the in situ formation of cells that looked and behaved like b cells, including an ability to rectify hyperglycemia. Unlike the iPS cell-based approach to cellular therapy, this direct conversion method has no risk of residual pluripotent cells. Instead, the main hurdles are the targeted delivery of the conversion agents to the appropriate areas and the prevention of partially converted or transformed cells. As with tissue metaplasia in the setting of tissue pathology, manipulation of cellular identity in vivo might carry the worrisome risk of neoplasia.
In addition to the experimental and possibly therapeutic tools generated by manipulating cellular identity in vitro, these techniques may provide new ways to study diseases of aberrant cell fates, such as metaplasia, neoplasm, and developmental disorders. It has not escaped anyone's notice that the original Yamanaka reprogramming factors-Oct4, Sox2, KLF4, and Myc-are in distinct contexts potent transforming oncogenes. Indeed, reprogramming mimics the dedifferentiation surmised In an experimental system with a reliable cellular disease phenotype readout, constancy of any two variables allows investigation of the other's effect on the disease phenotype.
for some tumors, and insights into the mechanisms of reprogramming are bound to yield new discoveries of mechanisms of oncogenic transformation. Because specific fate changes can now be induced in mammalian cells, researchers have the opportunity to interrogate the mechanisms by which a cell is coerced to change its identity, whether in the natural course of tissue differentiation, the distinctly pathologic course of dedifferentiation, the engineered fates of transdifferentiation, or the most dramatic of fate changes-reprogramming to pluripotency.
Conclusions
The discovery of cellular reprogramming and the realization that cellular identity is malleable and subject to engineering has compelled researchers to think in bold ways about new approaches to research disease mechanisms, drug development, and cell-based treatments for a range of diseases. However, recognizing that many diseases have significant environmental and epigenetic contributions, we anticipate that, in the near term, patient-specific stem cell-based disease models will be most useful for those disorders with highly penetrant genetic etiologies. In addition, we predict that this first wave of models will teach important lessons about precisely what aspects of pathophysiology can and cannot be gleaned from a diseasein-a-dish, including the impact of epigenetic memory and imperfect reprogramming on disease models. Using pluripotent stem cells to model diseases with only small genetic contributions may prove feasible but will present more formidable challenges. It will also depend on recapitulating environmental and epigenetic influences so that the relevant genetic and nongenetic factors collude to faithfully reproduce disease phenotypes in vitro. Given the pace of current research and the rapid accumulation of publications describing iPS cell-based disease models, the advantages and limitations of this new research platform are bound to come into focus, yielding principles that will guide future research within realistic expectations.
